

# Hannele Yki-Jrvinen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/845105/hannele-yki-jarvinen-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

223  
papers

22,262  
citations

80  
h-index

146  
g-index

235  
ext. papers

26,323  
ext. citations

8.3  
avg, IF

7.19  
L-index

#	Paper	IF	Citations
223	PSD3 downregulation confers protection against fatty liver disease.. <i>Nature Metabolism</i> , <b>2022</b> , 4, 60-75	14.6	1
222	Why does obesity cause diabetes?. <i>Cell Metabolism</i> , <b>2022</b> , 34, 11-20	24.6	15
221	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.. <i>JHEP Reports</i> , <b>2022</b> , 4, 100409	10.3	4
220	Effects of Bacterial Exposure on Secretion of Zonulin Family Peptides and Their Detection in Human Tissue Samples.. <i>Frontiers in Microbiology</i> , <b>2022</b> , 13, 848128	5.7	1
219	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	4
218	The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , <b>2021</b> ,	40	12
217	Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	12
216	Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	9
215	Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. <i>Gastroenterology</i> , <b>2021</b> , 160, 1634-1646.e7	13.3	23
214	Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. <i>Advanced Science</i> , <b>2021</b> , 8, 2004168	13.6	5
213	Dietary carbohydrates and fats in nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> , 18, 770-786	24.2	19
212	LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover. <i>Gut</i> , <b>2021</b> , 70, 180-193	19.2	39
211	The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e300-e315	5.6	5
210	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 20-30	13.4	24
209	Impact of short-term overfeeding of saturated or unsaturated fat or sugars on the gut microbiota in relation to liver fat in obese and overweight adults. <i>Clinical Nutrition</i> , <b>2021</b> , 40, 207-216	5.9	14
208	NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. <i>Liver International</i> , <b>2021</b> , 41, 2712-2719	7.9	3
207	Overfeeding Saturated Fat Increases LDL (Low-Density Lipoprotein) Aggregation Susceptibility While Overfeeding Unsaturated Fat Decreases Proteoglycan-Binding of Lipoproteins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2021</b> , 41, 2823-2836	9.4	2

206	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 770-785	13.4	19
205	Assessment of Lifestyle Factors Helps to Identify Liver Fibrosis Due to Non-Alcoholic Fatty Liver Disease in Obesity. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	3
204	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> ,	5.6	2
203	The PNPLA3-I148M variant increases polyunsaturated triglycerides in human adipose tissue. <i>Liver International</i> , <b>2020</b> , 40, 2128-2138	7.9	13
202	MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 725-726	13.4	16
201	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , <b>2020</b> , 158, 1999-2014.e1	13.3	748
200	Quantitative PCR provides a simple and accessible method for quantitative microbiota profiling. <i>PLoS ONE</i> , <b>2020</b> , 15, e0227285	3.7	93
199	OBEDIS Core Variables Project: European Expert Guidelines on a Minimal Core Set of Variables to Include in Randomized, Controlled Clinical Trials of Obesity Interventions. <i>Obesity Facts</i> , <b>2020</b> , 13, 1-28	5.1	5
198	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 202-209	13.4	764
197	Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 7347-7354	11.5	52
196	Hydroxysteroid 17- $\alpha$ -dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	33
195	Ceramides: A Cause of Insulin Resistance in Nonalcoholic Fatty Liver Disease in Both Murine Models and Humans. <i>Hepatology</i> , <b>2020</b> , 71, 1499-1501	11.2	11
194	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , <b>2020</b> , 98, 106175	2.3	28
193	Natural Course of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Patients With Human Immunodeficiency Virus With and Without Combination Antiretroviral Therapy-associated Lipodystrophy: A 16-Year Follow-up Study. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 1708-1716	11.6	4
192	Reply to Krahn and Sebastiani. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 245	11.6	
191	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 505-515	13.4	113
190	Effects of Weighted Hula-Hooping Compared to Walking on Abdominal Fat, Trunk Muscularity, and Metabolic Parameters in Overweight Subjects: A Randomized Controlled Study. <i>Obesity Facts</i> , <b>2019</b> , 12, 385-396	5.1	1
189	Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	48

188	Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 541-548	6.7	56
187	Fat accumulates preferentially in the right rather than the left liver lobe in non-diabetic subjects. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 168-174	3.3	3
186	Metabolomes of mitochondrial diseases and inclusion body myositis patients: treatment targets and biomarkers. <i>EMBO Molecular Medicine</i> , <b>2018</b> , 10,	12	33
185	Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars. <i>Diabetes Care</i> , <b>2018</b> , 41, 1732-1739	14.6	167
184	Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 128-136	13.4	70
183	Serum Insulin Bioassay Reflects Insulin Sensitivity and Requirements in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 3814-3821	5.6	3
182	Predictors of Liver Fat and Stiffness in Non-Alcoholic Fatty Liver Disease (NAFLD) - an 11-Year Prospective Study. <i>Scientific Reports</i> , <b>2017</b> , 7, 14561	4.9	14
181	Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. <i>Diabetologia</i> , <b>2017</b> , 60, 1873-1882	10.3	51
180	Obesity/insulin resistance rather than liver fat increases coagulation factor activities and expression in humans. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 286-294	7	15
179	Out of the frying pan: dietary saturated fat influences nonalcoholic fatty liver disease. <i>Journal of Clinical Investigation</i> , <b>2017</b> , 127, 454-456	15.9	16
178	Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , <b>2016</b> , 7, 8994	17.4	70
177	Noninvasive Detection of Nonalcoholic Steatohepatitis Using Clinical Markers and Circulating Levels of Lipids and Metabolites. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1463-1472.e6	6.9	82
176	Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 1167-1175	13.4	252
175	Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease. <i>Physiological Reports</i> , <b>2016</b> , 4, e12661	2.6	33
174	Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , <b>2016</b> , 18, 252-7	8.1	39
173	MicroRNA-192* impairs adipocyte triglyceride storage. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2016</b> , 1861, 342-51	5	20
172	Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels. <i>Diabetes Care</i> , <b>2016</b> , 39, e42-3	14.6	9
171	Influence of Ethnicity on the Accuracy of Non-Invasive Scores Predicting Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , <b>2016</b> , 11, e0160526	3.7	18

170	Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	80
169	Effects of treatment of NAFLD on the metabolic syndrome <b>2016</b> , 189-195		
168	Continuous Grading of Early Fibrosis in NAFLD Using Label-Free Imaging: A Proof-of-Concept Study. <i>PLoS ONE</i> , <b>2016</b> , 11, e0147804	3.7	24
167	Phosphorylated IGFBP-1 as a non-invasive predictor of liver fat in NAFLD. <i>Scientific Reports</i> , <b>2016</b> , 6, 247409	4.0	13
166	Diagnosis of non-alcoholic fatty liver disease (NAFLD). <i>Diabetologia</i> , <b>2016</b> , 59, 1104-11	10.3	52
165	The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 1263-1265	13.4	102
164	The influence of sample collection methodology and sample preprocessing on the blood metabolic profile. <i>Bioanalysis</i> , <b>2015</b> , 7, 991-1006	2.1	26
163	Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans. <i>Liver International</i> , <b>2015</b> , 35, 1853-61	7.9	48
162	Glucose toxicity <b>2015</b> , 413-425		3
161	Pathogenesis of nonalcoholic fatty liver disease (NAFLD) <b>2015</b> , 281-291		1
160	Impact of non-alcoholic fatty liver disease on liver volume in humans. <i>Hepatology Research</i> , <b>2015</b> , 45, 210-9	5.1	7
159	Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease. <i>Diabetes and Vascular Disease Research</i> , <b>2015</b> , 12, 249-57	3.3	11
158	Regulation of Angiopoietin-Like Proteins (ANGPTLs) 3 and 8 by Insulin. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, E1299-307	5.6	58
157	Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 657-63	13.4	84
156	Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin. <i>Diabetes Care</i> , <b>2015</b> , 38, e96-7	14.6	2
155	Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance. <i>Nutrients</i> , <b>2015</b> , 7, 9127-38	6.7	100
154	Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 607-16	5.6	35
153	Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity. <i>Diabetes</i> , <b>2014</b> , 63, 312-22	0.9	49

152	Effects of dietary interventions on liver volume in humans. <i>Obesity</i> , <b>2014</b> , 22, 989-95	8	23
151	Michaela Diamant, 11 April 1962-9 April 2014. <i>Diabetologia</i> , <b>2014</b> , 57, 1271-2	10.3	1
150	New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). <i>Diabetes Care</i> , <b>2014</b> , 37, 3235-43	14.6	210
149	Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. <i>Lancet Diabetes and Endocrinology</i> , <b>2014</b> , 2, 901-10	18.1	634
148	A population-based study on the prevalence of NASH using scores validated against liver histology. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 839-46	13.4	89
147	Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease. <i>Cell Cycle</i> , <b>2014</b> , 13, 1489-94	4.7	44
146	PNPLA3 mediates hepatocyte triacylglycerol remodeling. <i>Journal of Lipid Research</i> , <b>2014</b> , 55, 739-46	6.3	84
145	Altered miRNA processing disrupts brown/white adipocyte determination and associates with lipodystrophy. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 3339-51	15.9	128
144	Fatty liver score and 15-year incidence of type 2 diabetes. <i>Hepatology International</i> , <b>2013</b> , 7, 610-21	8.8	9
143	Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. <i>Diabetologia</i> , <b>2013</b> , 56, 2266-74	10.3	100
142	Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a 52-week randomized, double-blind study. <i>Diabetes Care</i> , <b>2013</b> , 36, 3875-81	14.6	111
141	Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling. <i>Diabetes</i> , <b>2013</b> , 62, 2539-44	0.9	18
140	17 $\beta$ Estradiol and estradiol fatty acyl esters and estrogen-converting enzyme expression in adipose tissue in obese men and women. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 4923-31	5.6	28
139	Is there evidence to support use of premixed or prandial insulin regimens in insulin-naïve or previously insulin-treated type 2 diabetic patients?. <i>Diabetes Care</i> , <b>2013</b> , 36 Suppl 2, S205-11	14.6	8
138	Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2012</b> , 27, 951-6	4	41
137	Metabolomic analysis of polar metabolites in lipoprotein fractions identifies lipoprotein-specific metabolic profiles and their association with insulin resistance. <i>Molecular BioSystems</i> , <b>2012</b> , 8, 2559-65		11
136	PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2012</b> , 302, E1063-9	6	71
135	Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. <i>American Journal of Clinical Nutrition</i> , <b>2012</b> , 96, 727-34	7	145

134	Isoform-specific alanine aminotransferase measurement can distinguish hepatic from extrahepatic injury in humans. <i>International Journal of Molecular Medicine</i> , <b>2012</b> , 30, 1241-9	4.4	13
133	Waist circumference adjusted for body mass index and intra-abdominal fat mass. <i>PLoS ONE</i> , <b>2012</b> , 7, e32213	3.7	18
132	Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. <i>Journal of Hepatology</i> , <b>2011</b> , 54, 153-9	13.4	101
131	Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2011</b> , 31, 176-83	7.9	67
130	FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. <i>Lancet Neurology</i> , <b>2011</b> , 10, 806-18	24.1	274
129	Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. <i>American Journal of Clinical Nutrition</i> , <b>2011</b> , 94, 104-11	7	104
128	Comparison of dorsocervical with abdominal subcutaneous adipose tissue in patients with and without antiretroviral therapy-associated lipodystrophy. <i>Diabetes</i> , <b>2011</b> , 60, 1894-900	0.9	14
127	Effects of exenatide on measures of $\beta$ -cell function after 3 years in metformin-treated patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2011</b> , 34, 2041-7	14.6	194
126	Association of lipidome remodeling in the adipocyte membrane with acquired obesity in humans. <i>PLoS Biology</i> , <b>2011</b> , 9, e1000623	9.7	169
125	Skeletal muscle mitochondrial DNA content and aerobic metabolism in patients with antiretroviral therapy-associated lipodystrophy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2010</b> , 65, 1497-504	5.1	2
124	Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. <i>Diabetes Care</i> , <b>2010</b> , 33, 1734-7	14.6	110
123	Allele-specific regulation of MTP expression influences the risk of ischemic heart disease. <i>Journal of Lipid Research</i> , <b>2010</b> , 51, 103-11	6.3	17
122	Use of genome-wide expression data to mine the "Gray Zone" of GWA studies leads to novel candidate obesity genes. <i>PLoS Genetics</i> , <b>2010</b> , 6, e1000976	6	56
121	Nonalcoholic fatty liver disease: detection of elevated nicotinamide adenine dinucleotide phosphate with in vivo $^3\text{T}$ $^3\text{P}$ MR spectroscopy with proton decoupling. <i>Radiology</i> , <b>2010</b> , 256, 466-73 <sup>20.5</sup>	42	
120	Liver fat in the pathogenesis of insulin resistance and type 2 diabetes. <i>Digestive Diseases</i> , <b>2010</b> , 28, 203-9. <sup>2</sup>	83	
119	From the metabolic syndrome to NAFLD or vice versa?. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 320-30	3.3	341
118	Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease. <i>Gastroenterology</i> , <b>2010</b> , 139, 1961-1971.e1	13.3	52
117	One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. <i>Atherosclerosis</i> , <b>2010</b> , 212, 223-9	3.1	101



116	Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , <b>2010</b> , 13, 709-14	3.8	52
115	Insulin Resistance in Type 2 Diabetes <b>2010</b> , 174-190		0
114	Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. <i>Diabetes</i> , <b>2009</b> , 58, 203-8	0.9	175
113	Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. <i>European Journal of Endocrinology</i> , <b>2009</b> , 160, 593-602	6.5	62
112	Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients. <i>Brain</i> , <b>2009</b> , 132, 933-9	11.2	137
111	Liver fat and lipid oxidation in humans. <i>Liver International</i> , <b>2009</b> , 29, 1439-46	7.9	65
110	One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. <i>Diabetes Care</i> , <b>2009</b> , 32, 762-8	14.6	327
109	Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 1035-42	13.4	103
108	Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. <i>Gastroenterology</i> , <b>2009</b> , 137, 865-72	13.3	469
107	Thiazolidinediones and the liver in humans. <i>Current Opinion in Lipidology</i> , <b>2009</b> , 20, 477-83	4.4	47
106	Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. <i>Gastroenterology</i> , <b>2008</b> , 135, 122-30	13.3	253
105	Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 2190-7	15.1	55
104	Fatty liver: a novel component of the metabolic syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2008</b> , 28, 27-38	9.4	626
103	Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. <i>Diabetes Care</i> , <b>2008</b> , 31, 165-9	14.6	156
102	Global transcript profiles of fat in monozygotic twins discordant for BMI: pathways behind acquired obesity. <i>PLoS Medicine</i> , <b>2008</b> , 5, e51	11.6	218
101	Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 118-24	5.6	42
100	Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 4867-72	5.6	54
99	Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. <i>Aids</i> , <b>2008</b> , 22, 227-36	3.5	63



98	Liver fat in the metabolic syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 3490-7	5.6	323
97	Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. <i>Clinical Endocrinology</i> , <b>2007</b> , 66, 440-6	3.4	134
96	Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. <i>Diabetes</i> , <b>2007</b> , 56, 1960-8	0.9	240
95	Insulin resistance, arterial stiffness and wave reflection. <i>Advances in Cardiology</i> , <b>2007</b> , 44, 252-260		40
94	Postprandial lipemia associates with liver fat content. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 3052-9	5.6	62
93	Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 720-4	5.6	65
92	Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. <i>Diabetes Care</i> , <b>2007</b> , 30, 1364-9	14.6	119
91	Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. <i>Diabetes</i> , <b>2007</b> , 56, 2759-65	0.9	248
90	Effect of liver fat on insulin clearance. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2007</b> , 293, E1709-15	6	159
89	Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , <b>2007</b> , 29, 1607-19	3.5	119
88	Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects--a monozygotic twin study. <i>PLoS ONE</i> , <b>2007</b> , 2, e218	3.7	306
87	Uridine supplementation for the treatment of antiretroviral therapy-associated lipotrophy: a randomized, double-blind, placebo-controlled trial. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 97-105	1.6	45
86	Acquired obesity increases CD68 and tumor necrosis factor-alpha and decreases adiponectin gene expression in adipose tissue: a study in monozygotic twins. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 2776-81	5.6	58
85	Fatty acid metabolism in adipose tissue, muscle and liver in health and disease. <i>Essays in Biochemistry</i> , <b>2006</b> , 42, 89-103	7.6	167
84	The PROactive study: some answers, many questions. <i>Lancet, The</i> , <b>2005</b> , 366, 1241-2	40	112
83	Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. <i>Diabetes Care</i> , <b>2005</b> , 28, 254-9	14.6	362
82	Dietary fat content modifies liver fat in overweight nondiabetic subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 2804-9	5.6	280
81	Fat in the liver and insulin resistance. <i>Annals of Medicine</i> , <b>2005</b> , 37, 347-56	1.5	202

80	Glycodelin responses to hyperinsulinaemic clamp vary according to basal serum glycodelin concentration. <i>Clinical Endocrinology</i> , <b>2005</b> , 62, 611-5	3.4	3
79	The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. <i>Diabetes</i> , <b>2005</b> , 54, 1364-70	0.9	85
78	Arterial Stiffness in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 925-935	1.6	26
77	Glargine and regular human insulin similarly acutely enhance endothelium-dependent vasodilatation in normal subjects. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2004</b> , 24, 320-4	9.4	16
76	3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2004</b> , 24, 325-30	9.4	60
75	Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 4414-21	5.6	189
74	Thiazolidinediones. <i>New England Journal of Medicine</i> , <b>2004</b> , 351, 1106-18	59.2	1697
73	Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. <i>Diabetes</i> , <b>2004</b> , 53, 2169-76	0.9	434
72	Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. <i>American Journal of Clinical Nutrition</i> , <b>2004</b> , 79, 22-30	7	66
71	Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. <i>Aids</i> , <b>2003</b> , 17, 1753-62	3.5	88
70	Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 1907-10	5.6	83
69	Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 4924-31	5.6	149
68	Differential effects of oral and transdermal estradiol treatment on circulating estradiol fatty acid ester concentrations in postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 588-93	5.6	15
67	Nonglycemic effects of insulin. <i>Clinical Cornerstone</i> , <b>2003</b> , Suppl 4, S6-12		12
66	Insulin- and exercise-stimulated skeletal muscle blood flow and glucose uptake in obese men. <i>Obesity</i> , <b>2003</b> , 11, 257-65		29
65	Insulin resistance and endothelial dysfunction. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 17, 411-30	6.5	49
64	Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes. <i>Diabetes Care</i> , <b>2003</b> , 26, 1667-72	14.6	62
63	Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. <i>Diabetes</i> , <b>2003</b> , 52, 701-7	0.9	222

62	Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2003</b> , 23, 688-94	9.4	63
61	Rosiglitazone in the Treatment of Haart-Associated Lipodystrophy in Randomized Double-Blind Placebo-Controlled Study. <i>Antiviral Therapy</i> , <b>2003</b> , 8, 199-207	1.6	106
60	Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2002</b> , 18 Suppl 3, S77-81	7.5	31
59	Endothelial dysfunction in human diabetes. <i>Current Diabetes Reports</i> , <b>2002</b> , 2, 26-36	5.6	34
58	Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes. <i>Obesity</i> , <b>2002</b> , 10, 859-67		119
57	Insulin-induced decreases in aortic wave reflection and central systolic pressure are impaired in type 2 diabetes. <i>Diabetes Care</i> , <b>2002</b> , 25, 2314-9	14.6	42
56	Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2002</b> , 22, 1637-41	9.4	177
55	Arterial stiffness and insulin resistance. <i>Seminars in Vascular Medicine</i> , <b>2002</b> , 2, 157-64		13
54	Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2002</b> , 22, 167-72	9.4	107
53	Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. <i>Aids</i> , <b>2002</b> , 16, 2183-93	3.5	139
52	Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 87, 3023-8	5.6	791
51	Ectopic fat accumulation: an important cause of insulin resistance in humans. <i>Journal of the Royal Society of Medicine</i> , <b>2002</b> , 95 Suppl 42, 39-45	2.3	23
50	Multiple risk factor intervention in type 2 diabetes: an opportunity not to be missed. <i>Diabetes, Obesity and Metabolism</i> , <b>2001</b> , 3, 1-8	6.7	8
49	Resistance to exercise-induced increase in glucose uptake during hyperinsulinemia in insulin-resistant skeletal muscle of patients with type 1 diabetes. <i>Diabetes</i> , <b>2001</b> , 50, 1371-7	0.9	33
48	Evidence for spatial heterogeneity in insulin- and exercise-induced increases in glucose uptake: studies in normal subjects and patients with type 1 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 5525-33	5.6	13
47	Resistance to acute insulin induced decreases in large artery stiffness accompanies the insulin resistance syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 5262-8	5.6	51
46	Regulation of hexokinase II expression in human skeletal muscle in vivo. <i>Metabolism: Clinical and Experimental</i> , <b>2000</b> , 49, 814-8	12.7	30
45	Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials. <i>Drugs</i> , <b>2000</b> , 60, 975-83	12.1	32

44	Independent influence of age on basal insulin secretion in nondiabetic humans. European Group for the Study of Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 863-8	5.6	175
43	Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus. <i>Drugs</i> , <b>1999</b> , 58 Suppl 1, 53-4; discussion 75-82	12.1	26
42	Glutamine: fructose-6-phosphate amidotransferase activity and gene expression are regulated in a tissue-specific fashion in pregnant rats. <i>Life Sciences</i> , <b>1999</b> , 65, 215-23	6.8	10
41	Intense physical training decreases circulating antioxidants and endothelium-dependent vasodilatation in vivo. <i>Atherosclerosis</i> , <b>1999</b> , 145, 341-9	3.1	139
40	Autoantibodies against oxidized LDL and endothelium-dependent vasodilation in insulin-dependent diabetes mellitus. <i>Atherosclerosis</i> , <b>1999</b> , 147, 115-22	3.1	18
39	Free fatty acid kinetics and oxidation in congestive heart failure. <i>American Journal of Cardiology</i> , <b>1998</b> , 81, 45-50	3	94
38	Toxicity of hyperglycaemia in Type 2 diabetes. <i>Diabetes/metabolism Reviews</i> , <b>1998</b> , 14, S45-S50		11
37	Insulin and glucosamine infusions increase O-linked N-acetyl-glucosamine in skeletal muscle proteins in vivo. <i>Metabolism: Clinical and Experimental</i> , <b>1998</b> , 47, 449-55	12.7	97
36	MODY genes and mutations in hepatocyte nuclear factors. <i>Lancet, The</i> , <b>1997</b> , 349, 516-7	4.0	14
35	Estimation of blood flow heterogeneity distribution in human skeletal muscle from positron emission tomography data. <i>Annals of Biomedical Engineering</i> , <b>1997</b> , 25, 906-10	4.7	22
34	The effect of insulin and FFA on myocardial glucose uptake. <i>Journal of Molecular and Cellular Cardiology</i> , <b>1995</b> , 27, 1359-67	5.8	52
33	Insulin increases the release of endothelin in endothelial cell cultures in vitro but not in vivo. <i>Metabolism: Clinical and Experimental</i> , <b>1994</b> , 43, 878-82	12.7	41
32	Pathogenesis of non-insulin-dependent diabetes mellitus. <i>Lancet, The</i> , <b>1994</b> , 343, 91-5	4.0	160
31	Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. <i>New England Journal of Medicine</i> , <b>1992</b> , 327, 1426-33	59.2	286
30	Glucose toxicity. <i>Endocrine Reviews</i> , <b>1992</b> , 13, 415-31	27.2	262
29	No Evidence for Short-Term Regulation of Plasminogen Activator Inhibitor Activity by Insulin in Man. <i>Thrombosis and Haemostasis</i> , <b>1992</b> , 67, 117-120	7	32
28	Effect of free fatty acids on glucose uptake and nonoxidative glycolysis across human forearm tissues in the basal state and during insulin stimulation. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1991</b> , 72, 1268-77	5.6	91
27	Evidence for a primary role of insulin resistance in the pathogenesis of type 2 diabetes. <i>Annals of Medicine</i> , <b>1990</b> , 22, 197-200	1.5	11

26	Changes in muscle glucose metabolism in type 1 diabetes. <i>Annals of Medicine</i> , <b>1990</b> , 22, 201-5	1.5	7
25	Regulation of plasma lactate concentration in resting human subjects. <i>Metabolism: Clinical and Experimental</i> , <b>1990</b> , 39, 859-64	12.7	44
24	Dose-response characteristics for suppression of low molecular weight plasma insulin-like growth factor-binding protein by insulin. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1989</b> , 68, 135-40	5.6	170
23	Prolonged exercise increases serum insulin-like growth factor-binding protein concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1989</b> , 68, 141-4	5.6	99
22	Severity, duration, and mechanisms of insulin resistance during acute infections. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1989</b> , 69, 317-23	5.6	97
21	Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. <i>American Journal of Medicine</i> , <b>1988</b> , 84, 185-92	2.4	46
20	Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1988</b> , 66, 266-72	5.6	454
19	Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. <i>New England Journal of Medicine</i> , <b>1988</b> , 318, 1217-25	59.2	490
18	No association between retinopathy and insulin resistance in type 1 diabetes. <i>European Journal of Endocrinology</i> , <b>1986</b> , 111, 522-7	6.5	1
17	Insulin binding and action in adipocytes in vitro in relation to insulin action in vivo in young and middle-aged subjects. <i>European Journal of Endocrinology</i> , <b>1986</b> , 113, 88-92	6.5	14
16	Relationship between oral glucose tolerance and insulin sensitivity in healthy man and type 1 diabetic patients. <i>European Journal of Endocrinology</i> , <b>1986</b> , 112, 355-60	6.5	6
15	Natural course of insulin resistance in type I diabetes. <i>New England Journal of Medicine</i> , <b>1986</b> , 315, 224-30	39.2	287
14	Smoking and insulin sensitivity in type I diabetic patients. <i>Metabolism: Clinical and Experimental</i> , <b>1986</b> , 35, 874-7	12.7	29
13	Insulin resistance is a prominent feature of patients with pancreatogenic diabetes. <i>Metabolism: Clinical and Experimental</i> , <b>1986</b> , 35, 718-27	12.7	42
12	The effect of exogenous hyperinsulinemia on proinsulin secretion in normal man, obese subjects, and patients with insulinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1986</b> , 63, 1117-20	5.6	38
11	Ethanol decreases glucose utilization in healthy man. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1985</b> , 61, 941-5	5.6	107
10	Site of insulin resistance in type 1 diabetes: insulin-mediated glucose disposal in vivo in relation to insulin binding and action in adipocytes in vitro. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1984</b> , 59, 1183-92	5.6	48
9	The occurrence of relaxin in hyperstimulated human preovulatory follicles collected in an in vitro fertilization program. <i>Journal of In Vitro Fertilization and Embryo Transfer: IVF</i> , <b>1984</b> , 1, 180-2		6

8	Insulin sensitivity in newly diagnosed type 1 diabetics after ketoacidosis and after three months of insulin therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1984</b> , 59, 371-8	5.6	80
7	Continuous subcutaneous insulin infusion therapy decreases insulin resistance in type 1 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1984</b> , 58, 659-66	5.6	113
6	Sex and insulin sensitivity. <i>Metabolism: Clinical and Experimental</i> , <b>1984</b> , 33, 1011-5	12.7	133
5	Immunohistochemical demonstration of relaxin in gynecologic tumors. <i>Cancer</i> , <b>1983</b> , 52, 2077-80	6.4	6
4	Solubilization and preliminary characterization of the human ileal vitamin B12-intrinsic factor receptor. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>1979</b> , 39, 461-7	2	5
3	Growth Patterns in Young Adult Monozygotic Twin Pairs Discordant and Concordant for Obesity		1
2	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease		1
1	Quantitative PCR provides a simple and accessible method for quantitative microbiome profiling		11